Catalyst Biosciences - Top 20 VC deals of 2008

Catalyst Biosciences, FierceBiotech's top venture capital deals of 2008Company: Catalyst Biosciences
Based: South San Francisco, CA
Amount: $40.28M

Investors: Johnson & Johnson Development Corporation, Undisclosed Venture Firm, Essex Woodlands Health Ventures, Burrill & Company, Novartis Venture Fund, HealthCare Ventures, Morgenthaler Ventures, Sofinnova Ventures

Scoop: Catalyst programs redirect protein-degrading enzymes (called Alterases) to degrade specific proteins that promote disease. It's third round of funding, raised in December, gave the company cash to build its pipeline of Alterase therapeutics. Catalyst is advancing its lead protease, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, through Phase I/II proof-of-concept studies in patients.

Catalyst Biosciences - Top 20 VC deals of 2008
Read more on

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.